NKCx Histopathological outcome* within 12 months after cervix cytology in 2024
271 Blekinge

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 264 19.4% 24 1.8% 6 0.4% 1 0.1% . . . . 1068 78.4% 1363 100.0%
ASCUS 80 44.7% 31 17.3% 8 4.5% . . . . . . 60 33.5% 179 100.0%
LSIL 64 28.6% 90 40.2% 12 5.4% . . . . . . 58 25.9% 224 100.0%
Atypical glandular cells/AGC 11 55.0% 2 10.0% 1 5.0% 2 10.0% . . . . 4 20.0% 20 100.0%
Unclear atypia 1 25.0% . . 1 25.0% 1 25.0% . . . . 1 25.0% 4 100.0%
ASC-H 9 16.4% 18 32.7% 22 40.0% 1 1.8% 2 3.6% . . 3 5.5% 55 100.0%
HSIL 2 4.7% 6 14.0% 31 72.1% 1 2.3% 2 4.7% . . 1 2.3% 43 100.0%
Suspected Adenocarcinom . . . . . . 1 33.3% 1 33.3% . . 1 33.3% 3 100.0%
Squamous cell cancer . . . . 1 14.3% . . 4 57.1% . . 2 28.6% 7 100.0%
Totalt 431 22.7% 171 9.0% 82 4.3% 7 0.4% 9 0.5% . . 1198 63.1% 1898 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the
category Cancer:
M80703, M84613